Cervomed Inc. · NASDAQ:CRVO
Cervomed — Investor Presentation (December 2024)
13 slides from Cervomed's investor presentation, Dec 10, 2024
Slide 1: CervoMed Corporate Overview December 2024
§ CERVOMED Medicines for the Brain Corporate Overview December 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation indides expxess ond implied forward-looking stolements within the meaning of the Private Secures Litigation Reform Ad of 1995, es emended, regarding the Intntons, plans, ballets, expectations of forecasts forthe future of CervaMed nc. the “Compony’), ndud
Slide 3: Company Overview
Company Overview Targeting the Early Stage of the Neurodegenerative Process, Synaptic Dysfunction, to Treat Age-Related Neurologic Disorders CervoMed began trading on NASDAQ (CRVO) in August 2023 following a completed merger between EIP Pharma, Inc. and Diffusion Pharmaceuticals Inc. Headquartered:
Slide 4: Leadership Team and Scientific Advisors
nced Leadership Team Pipher she ge PHD (Ch Jone H.Hlings woth, 1D Prevent, CEO & Co Founda, Decor ; " 7 Eecotve Ch, Alen Tropes ‘Managing are Veen ee Se 0 ee rr Fede rme CEO Varn Perma Former Chon he Bor ion inkl devant of Arn fr male rth ot Bapen Ps Cenday ad mene Mere Hdl #26, Ativan, Marwan Sbbep
Slide 5: Financial Overview
Financial Overview! )» Cash Resources and Grant Funding + $46.7§ in cash, cash equivalents and marketable securities os of September30, 2024 + $21.3M NIA Grant originally awarded January '23, disbursed over course of RewinD-LB trial CervoMed has an expected cash runway + $6.2M in remaining NIA grant
Slide 6: CervoMed Pipeline
CervoMed Pipeline PRECLINICAL PHASE PHASE 2 PHASES Milestones NEFLAMAPIMOD VT scorer Recovery alter Ischemic Stroke tat total iyi Frontotemporal dementia®* oem Alzheimer’s disease E1P200 (novel co-crystal) ‘Multiple CNS Werdide commerce! ihe acres progton ‘ecaved OA ow Wo sgn ‘toca FO Orphen Erg deg
Slide 7: Neflamapimod Mechanism of Action
Neflamapimod Mechanism of Action Oral p38a Kinase Inhibitor Targeting Cholinergic Dysfunction and Degeneration B-CTF of APP! —_Neuroinflammation, a- | synuclein, AB (-) j Neflamapimod Synaptic Dysfunction, Tau Hyp rt and Ne Beto Forebrain Chotinergie (BEC) Complex Release of actylcholine through cor
Slide 8: Dementia with Lewy Bodies (DLB)
Dementia with Lewy Bodies (DLB) 7 DLB associated with abnormal deposits (“Lewy bodies") within neurons of @ protein called «lpha-synuclein inthe brain. Primary site of pathology is basal forebrain Clinically, characterized by dementia and 2 2 of the following: fluctuating attention, visual hallucina
Slide 9: Clinical Course of DLB Creates Unique Opportunities for Therapeutic Intervention
Clinical Course of DLB Creates Unique Opportunities for Therapeutic Intervention Alzheimer's disease \D) related Prevalence biomarker Basal Forebrain Temporal Lobe to Partially Cholinergic System (Hippocampus) Restore Function ’ . ! Yes, with a drug ! nets Approximately 50% of J evipstope LB hid Som
Slide 10: Neflamapimod: Targeted Therapy for Diseases of the Basal Forebrain
Neflamapimod: Targeted Therapy for Diseases of the Basal Forebrain Disease processes in basal forebrain reversed with neflamapimod ) When administered in mice that develop basal forebrain cholinergic degeneration, neflamapimod: Reduced RabS activity and tau phosphorylation Y Reversed loss of choline
Slide 11: RewinD-LB Phase 2b in Early-Stage DLB
RewinD-LB Phase 2b in Early-Stage DLB Rewin))-1B ° ° O° + TRIAL OVERVIEW KEY OUTCOME MEASURES DLB by contenws criteria: Primary: Clinical Dementia Rating Som of Boxes (COR-SB) Pretreatment plasma piavi@1 <2.4 pg/ml Secondary: Timed Up andl Go (TUG) txt, Newropsychological Test Botery N= 159 partipon
Slide 12: RewinD-LB Topline Data Summary
RewinD-LB Topline Data Summary Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks Target plasma drug concentrations not achieved during the double-blind phase of the trial; investigation of cause ongoing Favorable safety a
Slide 13: CervoMed Medicines for the Brain
§ CERVOMED Medicines for the Brain Corporate Overview December 2024